ClinicalTrials.gg
TerminatedNCT01473758TREATUpdated Feb 14, 2017Results posted

Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of Roflumilast and Placebo in Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation, sponsored by AstraZeneca. Terminated at 2 sites in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-02-14.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Why this study was terminated
Company decision: No Safety or Efficacy Concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
18th of 32
81 · median 154
Started
2012
with 3 others
Phase 2
4 of 32
none open now
Registered
16th of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 18th largest by enrollment, is one of 4 that started in 2012, is one of 4 in phase 2, and was the 16th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). In addition, the potential benefit of roflumilast on severity and recovery periods of acute COPD exacerbations will be assessed using patient diaries and questionnaires.

Read the detailed description

Participants will be asked whether they agree to participate in the measurements of arterial stiffness. Participants who agree will be included in the substudy, with the target of 60 patients with arterial stiffness measurements to complete the trial.

Study was terminated due to difficulty in identifying further eligible patients for this exploratory study within a reasonable time.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation

Keywords

  • COPD
  • Chronic obstructive pulmonary disease
  • Roflumilast
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Written (IC)
  • Age ≥ 40 years
  • History of for at least 12 months prior to enrollment (Visit V0)
  • Chronic productive cough for 3 months in each of the 2 years prior to enrollment (if other causes of productive cough have been excluded) and/or an exacerbation with predominantly bronchitic symptoms at enrollment
  • Presentation of an acute exacerbation of COPD that will be associated with increased sputum volume or change in sputum colour
  • Documented fixed airway obstruction determined by an /FVC ratio (post-bronchodilator) \< 70% (if a pulmonary function test is not possible at Visit V0 a previous measurement can be taken which must not be older than 6 months)
  • Former smoker (defined as: smoking cessation at least 1 year ago) or current smoker both with a smoking history of at least 10 pack years

Main Exclusion Criteria:

  • Diagnosis of asthma and/or other relevant lung disease
  • Known alpha-1-antitrypsin deficiency
  • Recurrent exacerbations (within 8 weeks of a preceding exacerbation)
  • Treatment of current exacerbation with oral and/or antibiotics already started at enrollment
  • Treatment with PDE4 inhibitors within 3 months prior to Visit V0
  • Other protocol-defined exclusion criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
81 participants (actual)

Study arms

  • Active comparator
    Roflumilast

    added on to standard therapy for acute COPD exacerbations

    Drug: Roflumilast

  • Placebo comparator
    Placebo

    added on to standard therapy for acute COPD exacerbations

    Drug: Placebo

Interventions

  • 500 µg tablet, od, oral administration in the morning after breakfast

  • DrugPlacebo

    tablet, od, oral administration in the morning after breakfast

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. An Analysis of Covariance (ANCOVA) model was used with neutrophil count at Baseline and treatment as independent variables, fixed effects.

    Time frame: Baseline and Day 14

  2. Change From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. An Analysis of Covariance (ANCOVA) model was used with neutrophil count at Baseline and treatment as independent variables, fixed effects.

    Time frame: Baseline and Day 14

Secondary outcomes

  1. Percentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) and were determined with a Neubauer hemocytometer.

    Time frame: Day 14

  2. Percentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) and were determined with a Neubauer hemocytometer.

    Time frame: Day 14

  3. Change From Baseline in Sputum Marker Total Cells (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  4. Change From Baseline in Sputum Marker Total Cells (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  5. Change From Baseline in Sputum Marker Percentage of Neutrophils (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of neutrophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  6. Change From Baseline in Sputum Marker Percentage of Neutrophils (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of neutrophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  7. Change From Baseline in Sputum Marker Percentage of Macrophages (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of macrophages was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  8. Change From Baseline in Sputum Marker Percentage of Macrophages (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of macrophages was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  9. Change From Baseline in Sputum Marker Percentage of Eosinophils (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of eosinophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  10. Change From Baseline in Sputum Marker Percentage of Eosinophils (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of eosinophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  11. Change From Baseline in Sputum Marker Percentage of Lymphocyte (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of lymphocytes was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  12. Change From Baseline in Sputum Marker Percentage of Lymphocytes (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of lymphocytes was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  13. Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-6 (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-6 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  14. Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-6 (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-6 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  15. Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-8 (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-8 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  16. Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-8 (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-8 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  17. Change From Baseline in Sputum Marker Concentration of Myeloperoxidase (MPO) (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker MPO was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  18. Change From Baseline in Sputum Marker Concentration of Myeloperoxidase (MPO) (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker MPO was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  19. Change From Baseline in Sputum Marker Concentration of Neutrophil Elastase (Initial Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker Neutrophil Elastase was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  20. Change From Baseline in Sputum Marker Concentration of Neutrophil Elastase (Extended Approach)

    Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker Neutrophil Elastase was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  21. Change From Baseline in Blood Biomarker Interleukin (IL)-6 (Initial Approach)

    Blood was collected and serum biomarker IL-6 was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  22. Change From Baseline in Blood Biomarker Interleukin (IL)-6 (Extended Approach)

    Blood was collected and serum biomarker IL-6 was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  23. Change From Baseline in Blood Biomarker Interleukin-1 Beta (IL-1β) (Initial Approach)

    Blood was collected and serum biomarker IL-1β was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  24. Change From Baseline in Blood Biomarker IL-1β (Extended Approach)

    Blood was collected and serum biomarker IL-1β was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  25. Change From Baseline in Blood Biomarker C-reactive Protein (CRP) (Initial Approach)

    Blood was collected and serum biomarker CRP was measured using Roche Modular Analytics E 170 Module. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  26. Change From Baseline in Blood Biomarker C-reactive Protein (CRP) (Extended Approach)

    Blood was collected and serum biomarker CRP was measured using Roche Modular Analytics E 170 Module. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  27. Change From Baseline in Blood Biomarker Fibrinogen (Initial Approach)

    Biomarker Plasma fibrinogen was determined using the method described by Clauss. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  28. Change From Baseline in Blood Biomarker Fibrinogen (Extended Approach)

    Biomarker Plasma fibrinogen was determined using the method described by Clauss. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  29. Change From Baseline in Blood Biomarker Glucose (Initial Approach)

    Blood was collected and analyzed for serum glucose levels. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  30. Change From Baseline in Blood Biomarker Glucose (Extended Approach)

    Blood was collected and analyzed for serum glucose levels. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  31. Change From Baseline in Forced Expiratory Volume (FEV1) (Initial Approach)

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  32. Change From Baseline in Forced Expiratory Volume (FEV1) (Extended Approach)

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  33. Change From Baseline in Forced Vital Capacity (FVC) (Initial Approach)

    Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  34. Change From Baseline in Forced Vital Capacity (FVC) (Extended Approach)

    Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  35. Change From Baseline in FEV1/FVC (Initial Approach)

    FEV1/FVC is the percentage of the vital capacity which is expired in the first second of maximal expiration. In healthy patients the FEV1/FVC is usually around 70%. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  36. Change From Baseline in FEV1/FVC (Extended Approach)

    FEV1/FVC is the percentage of the vital capacity which is expired in the first second of maximal expiration. In healthy patients the FEV1/FVC is usually around 70%. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

    Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56

  37. Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Initial Approach)

    The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  38. Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Extended Approach)

    The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  39. Change From Stable State in Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Initial Approach)

    The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst). A negative change from Baseline indicates improvement. Covariates for MMRM are stable state value, treatment, time point, and treatment by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  40. Change From Stable State in Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Extended Approach)

    The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst). A negative change from Baseline indicates improvement. Covariates for MMRM are stable state value, treatment, time point, and treatment by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  41. Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Initial Approach)

    The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status.

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  42. Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Extended Approach)

    The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status.

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  43. Change From Stable State in Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Initial Approach)

    The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, time point, treatment by time point and baseline by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  44. Change From Stable State in Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Extended Approach)

    The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, time point, treatment by time point and baseline by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  45. Change From Stable State in Diaries Peak Expiratory Flow (PEF) Weekly Average (Initial Approach)

    Morning post-medication PEF (the best of 3 attempts measured with a mini-Wright peak-flow meter) was recorded in a daily diary. A positive change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  46. Change From Stable State in Diaries Peak Expiratory Flow (PEF) Weekly Average (Extended Approach)

    Morning post-medication PEF (the best of 3 attempts measured with a mini-Wright peak-flow meter) was recorded in a daily diary. A positive change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  47. Change From Stable State in Diaries Symptom Score Weekly Average (Initial Approach)

    Any increase in the following respiratory symptoms: dyspnea, sputum purulence, sputum amount, wheeze, sore throat, cough, fever, symptoms of a common cold, ie, nasal congestion and discharge over the previous 24 hours were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  48. Change From Stable State in Diaries Symptom Score Weekly Average (Extended Approach)

    Any increase in the following respiratory symptoms: dyspnea, sputum purulence, sputum amount, wheeze, sore throat, cough, fever, symptoms of a common cold, ie, nasal congestion and discharge over the previous 24 hours were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  49. Change From Stable State in Diaries Treatment Score Weekly Average (Initial Approach)

    Any changes in the participant's usual treatment were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  50. Change From Stable State in Diaries Treatment Score Weekly Average (Extended Approach)

    Any changes in the participant's usual treatment were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  51. Change From Stable State in Diaries Hours Out of the Home Weekly Average (Initial Approach)

    Estimates of the length of time the participants were out of their own home on the previous day were recorded in a daily diary. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  52. Change From Stable State in Diaries Hours Out of the Home Weekly Average (Extended Approach)

    Estimates of the length of time the participants were out of their own home on the previous day were recorded in a daily diary. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8

  53. Exacerbation Length (Initial Approach)

    Exacerbation length is the period from start of increased symptoms to end of increased symptoms; the last day of an exacerbation was to be followed by 2 days without symptom entries in the diary.

    Time frame: 8 Weeks

  54. Exacerbation Length (Extended Approach)

    Exacerbation length is the period from start of increased symptoms to end of increased symptoms; the last day of an exacerbation was to be followed by 2 days without symptom entries in the diary.

    Time frame: 8 Weeks

  55. Change From Baseline in Aortic Pulse Wave Velocity in a Subset of Participants (Initial Approach)

    Carotid-femoral aortic pulse wave velocity (aPWV) will be measured in a subset of participants to determine changes in arterial stiffness. A negative change from Baseline indicates improvement. Covariates for MMRM are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Days 14 and 28

  56. Change From Baseline in Aortic Pulse Wave Velocity in a Subset of Participants (Extended Approach)

    Carotid-femoral aortic pulse wave velocity (aPWV) will be measured in a subset of participants to determine changes in arterial stiffness. A negative change from Baseline indicates improvement. Covariates for MMRM are baseline value, treatment, visit, and treatment by visit interaction.

    Time frame: Baseline and Days 14 and 28

07

Results

Posted Oct 24, 2016

Participant flow

Participants took part in the study at 1 investigative site in the United Kingdom from 16 February 2012 to 25 March 2014.

Cycle 1
Participant flow — Cycle 1
MilestoneRoflumilast 500 μgPlaceboRoflumilast 500 µg (Cycle 2)Placebo (Cycle 2)
Started384300
Completed274000
Not completed11300
Withdrew: Adverse event10200
Withdrew: Withdrawal by subject1100
Cycle 2
Participant flow — Cycle 2
MilestoneRoflumilast 500 μgPlaceboRoflumilast 500 µg (Cycle 2)Placebo (Cycle 2)
Started00104
Completed0054
Not completed0050
Withdrew: Adverse event0050

Outcome measures

PrimaryChange From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. An Analysis of Covariance (ANCOVA) model was used with neutrophil count at Baseline and treatment as independent variables, fixed effects.

Time frame:
Baseline and Day 14
Reported as:
Least squares mean · 10^6 cells/gram sputum
Change From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Initial Approach)
10^6 cells/gram sputumRoflumilast 500 μgPlacebo
Change From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Initial Approach)-18.705 ± 2.263-20.109 ± 1.995
Statistical analysis
  • Roflumilast 500 μg vs Placebo · ANCOVA · p = 0.6491 (The model contains neutrophil count at Baseline and treatment as independent variables, fixed effects.) · Ls mean difference: 1.404 · 95% CI -4.731 to 7.538
PrimaryChange From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. An Analysis of Covariance (ANCOVA) model was used with neutrophil count at Baseline and treatment as independent variables, fixed effects.

Time frame:
Baseline and Day 14
Reported as:
Least squares mean · 10^6 cells/gram sputum
Change From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Extended Approach)
10^6 cells/gram sputumRoflumilast 500 μgPlacebo
Change From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Extended Approach)-19.569 ± 1.906-19.157 ± 1.855
Statistical analysis
  • Roflumilast 500 μg vs Placebo · ANCOVA · p = 0.8786 (The model contains neutrophil count at Baseline and treatment as independent variables, fixed effects.) · Ls mean difference: -0.412 · 95% CI -5.766 to 4.943
SecondaryPercentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) and were determined with a Neubauer hemocytometer.

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Initial Approach)
percentage of participantsRoflumilast 500 μgPlacebo
Percentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Initial Approach)37.5 (15.2 to 64.6)55.2 (35.7 to 73.6)
SecondaryPercentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) and were determined with a Neubauer hemocytometer.

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Extended Approach)
percentage of participantsRoflumilast 500 μgPlacebo
Percentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Extended Approach)45.0 (23.1 to 68.5)51.6 (33.1 to 69.8)
SecondaryChange From Baseline in Sputum Marker Total Cells (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · 10^6 cells/gram sputum
Change From Baseline in Sputum Marker Total Cells (Initial Approach)
10^6 cells/gram sputumRoflumilast 500 μgPlacebo
Change at Day 7 (n=35, 39)-25.559 ± 3.529-27.563 ± 3.334
Change at Day 14 (n=32, 38)-21.813 ± 2.706-25.111 ± 2.505
Change at Day 28 (n=25, 37)-29.200 ± 4.022-22.218 ± 3.362
Change at Day 56 (n=24, 33)-24.477 ± 2.708-26.474 ± 2.341
SecondaryChange From Baseline in Sputum Marker Total Cells (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · 10^6 cells/gram sputum
Change From Baseline in Sputum Marker Total Cells (Extended Approach)
10^6 cells/gram sputumRoflumilast 500 μgPlacebo
Change at Day 7 (n=45, 43)-26.634 ± 3.030-26.335 ± 3.124
Change at Day 14 (n=41, 42)-23.512 ± 2.448-25.332 ± 2.471
Change at Day 28 (n=30, 40)-29.023 ± 3.347-22.920 ± 2.947
Change at Day 56 (n=28, 36)-19.551 ± 3.920-26.855 ± 3.536
SecondaryChange From Baseline in Sputum Marker Percentage of Neutrophils (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of neutrophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · percentage of neutrophils
Change From Baseline in Sputum Marker Percentage of Neutrophils (Initial Approach)
percentage of neutrophilsRoflumilast 500 μgPlacebo
Change at Day 7 (n=30, 35)-11.325 ± 3.837-14.484 ± 3.559
Change at Day 14 (n=31, 37)-16.770 ± 3.983-20.346 ± 3.550
Change at Day 28 (n=24, 34)-27.760 ± 5.275-13.837 ± 4.498
Change at Day 56 (n=16, 30)-19.663 ± 5.561-17.047 ± 4.229
SecondaryChange From Baseline in Sputum Marker Percentage of Neutrophils (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of neutrophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · percentage of neutrophils
Change From Baseline in Sputum Marker Percentage of Neutrophils (Extended Approach)
percentage of neutrophilsRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 39)-14.637 ± 3.748-16.060 ± 3.713
Change at Day 14 (n=39, 40)-20.690 ± 3.758-21.052 ± 3.678
Change at Day 28 (n=29, 36)-29.848 ± 4.721-14.664 ± 4.371
Change at Day 56 (n=20, 32)-21.327 ± 5.009-17.328 ± 4.188
SecondaryChange From Baseline in Sputum Marker Percentage of Macrophages (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of macrophages was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · percentage of macrophages
Change From Baseline in Sputum Marker Percentage of Macrophages (Initial Approach)
percentage of macrophagesRoflumilast 500 μgPlacebo
Change at Day 7 (n=30, 35)11.393 ± 3.83715.430 ± 3.559
Change at Day 14 (n=31, 37)16.062 ± 3.92920.774 ± 3.506
Change at Day 28 (n=24, 34)27.535 ± 5.28413.382 ± 4.503
Change at Day 56 (n=16, 30)16.593 ± 5.53915.877 ± 4.171
SecondaryChange From Baseline in Sputum Marker Percentage of Macrophages (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of macrophages was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · percentage of macrophages
Change From Baseline in Sputum Marker Percentage of Macrophages (Extended Approach)
percentage of macrophagesRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 39)14.679 ± 3.74017.228 ± 3.704
Change at Day 14 (n=39, 40)20.331 ± 3.74521.599 ± 3.667
Change at Day 28 (n=29, 36)29.510 ± 4.71714.463 ± 4.367
Change at Day 56 (n=20, 32)19.075 ± 5.00316.322 ± 4.156
SecondaryChange From Baseline in Sputum Marker Percentage of Eosinophils (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of eosinophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · percentage of eosinophils
Change From Baseline in Sputum Marker Percentage of Eosinophils (Initial Approach)
percentage of eosinophilsRoflumilast 500 μgPlacebo
Change at Day 7 (n=30, 35)-0.259 ± 0.245-0.100 ± 0.225
Change at Day 14 (n=31, 37)-0.110 ± 0.326-0.188 ± 0.288
Change at Day 28 (n=24, 34)0.043 ± 1.2091.597 ± 1.020
Change at Day 56 (n=16, 30)2.187 ± 2.2781.086 ± 1.766
SecondaryChange From Baseline in Sputum Marker Percentage of Eosinophils (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of eosinophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · percentage of macrophages
Change From Baseline in Sputum Marker Percentage of Eosinophils (Extended Approach)
percentage of macrophagesRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 39)-0.341 ± 0.206-0.141 ± 0.202
Change at Day 14 (n=39, 40)-0.174 ± 0.271-0.214 ± 0.263
Change at Day 28 (n=29, 36)0.031 ± 1.0441.518 ± 0.952
Change at Day 56 (n=20, 32)1.714 ± 1.9690.913 ± 1.655
SecondaryChange From Baseline in Sputum Marker Percentage of Lymphocyte (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of lymphocytes was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · percentage of lymphocytes
Change From Baseline in Sputum Marker Percentage of Lymphocyte (Initial Approach)
percentage of lymphocytesRoflumilast 500 μgPlacebo
Change at Day 7 (n=30, 35)0.229 ± 0.3530.182 ± 0.326
Change at Day 14 (n=31, 37)0.430 ± 0.2540.295 ± 0.225
Change at Day 28 (n=24, 34)0.039 ± 0.183-0.325 ± 0.155
Change at Day 56 (n=16, 30)-0.095 ± 0.187-0.051 ± 0.137
SecondaryChange From Baseline in Sputum Marker Percentage of Lymphocytes (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of lymphocytes was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · percentage of lymphocytes
Change From Baseline in Sputum Marker Percentage of Lymphocytes (Extended Approach)
percentage of lymphocytesRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 39)0.109 ± 0.308-0.015 ± 0.303
Change at Day 14 (n=39, 40)0.309 ± 0.2500.195 ± 0.243
Change at Day 28 (n=29, 36)-0.118 ± 0.173-0.431 ± 0.158
Change at Day 56 (n=20, 32)-0.203 ± 0.164-0.208 ± 0.132
SecondaryChange From Baseline in Sputum Marker Concentration of Interleukin (IL)-6 (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-6 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · pg/mL
Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-6 (Initial Approach)
pg/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=31, 38)-1317.400 ± 143.748-934.624 ± 133.217
Change at Day 14 (n=30, 35)-822.715 ± 221.328-695.955 ± 206.201
Change at Day 28 (n=22, 35)-1232.929 ± 212.663-955.365 ± 174.734
Change at Day 56 (n=22, 29)-1042.097 ± 225.619-996.485 ± 196.729
SecondaryChange From Baseline in Sputum Marker Concentration of Interleukin (IL)-6 (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-6 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · pg/mL
Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-6 (Extended Approach)
pg/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 42)-1207.678 ± 133.298-923.325 ± 130.533
Change at Day 14 (n=36, 39)-725.454 ± 195.921-705.849 ± 192.890
Change at Day 28 (n=26, 38)-1115.741 ± 200.367-877.871 ± 172.950
Change at Day 56 (n=26, 32)-860.191 ± 206.289-962.342 ± 189.817
SecondaryChange From Baseline in Sputum Marker Concentration of Interleukin (IL)-8 (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-8 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · pg/mL
Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-8 (Initial Approach)
pg/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=31, 38)-174718.396 ± 45481.710-227274.816 ± 41821.023
Change at Day 14 (n=30, 35)-149198.139 ± 47388.834-199515.687 ± 43965.789
Change at Day 28 (n=22, 35)-255317.294 ± 70915.154-160587.365 ± 57944.793
Change at Day 56 (n=21, 29)-204731.356 ± 50404.332-223918.341 ± 43039.568
SecondaryChange From Baseline in Sputum Marker Concentration of Interleukin (IL)-8 (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-8 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · pg/mL
Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-8 (Extended Approach)
pg/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 42)-193222.856 ± 39595.196-215296.477 ± 38432.424
Change at Day 14 (n=36, 39)-172069.810 ± 41341.330-195751.307 ± 40449.866
Change at Day 28 (n=26, 38)-264788.038 ± 62440.420-160441.028 ± 53963.528
Change at Day 56 (n=25, 32)-168204.970 ± 51760.361-205822.814 ± 46476.985
SecondaryChange From Baseline in Sputum Marker Concentration of Myeloperoxidase (MPO) (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker MPO was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · ng/mL
Change From Baseline in Sputum Marker Concentration of Myeloperoxidase (MPO) (Initial Approach)
ng/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=31, 38)-9253.786 ± 1997.077-4521.397 ± 1863.867
Change at Day 14 (n=30, 35)-8072.784 ± 2144.895-6318.878 ± 2002.939
Change at Day 28 (n=22, 35)-13744.824 ± 2476.123-5944.184 ± 2041.587
Change at Day 56 (n=22, 29)-10248.612 ± 2578.146-9478.460 ± 2234.238
SecondaryChange From Baseline in Sputum Marker Concentration of Myeloperoxidase (MPO) (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker MPO was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · ng/mL
Change From Baseline in Sputum Marker Concentration of Myeloperoxidase (MPO) (Extended Approach)
ng/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 42)-8606.357 ± 1747.094-4380.803 ± 1713.047
Change at Day 14 (n=36, 39)-8380.855 ± 1871.930-5929.775 ± 1843.806
Change at Day 28 (n=26, 38)-12692.279 ± 2220.374-5351.001 ± 1933.964
Change at Day 56 (n=26, 32)-9424.227 ± 2275.981-8527.766 ± 2078.411
SecondaryChange From Baseline in Sputum Marker Concentration of Neutrophil Elastase (Initial Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker Neutrophil Elastase was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · µg/mL
Change From Baseline in Sputum Marker Concentration of Neutrophil Elastase (Initial Approach)
µg/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=31, 38)-222995.020 ± 14887.254-224606.396 ± 13669.986
Change at Day 14 (n=30, 35)-149211.318 ± 39523.470-125385.276 ± 36629.962
Change at Day 28 (n=22, 35)-200905.068 ± 25432.984-149865.936 ± 20549.567
Change at Day 56 (n=21, 30)-141985.838 ± 28278.566-169389.587 ± 23767.879
SecondaryChange From Baseline in Sputum Marker Concentration of Neutrophil Elastase (Extended Approach)

Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker Neutrophil Elastase was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · µg/mL
Change From Baseline in Sputum Marker Concentration of Neutrophil Elastase (Extended Approach)
µg/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 42)-202235.344 ± 12993.506-206912.465 ± 12543.143
Change at Day 14 (n=36, 39)-143831.510 ± 34043.871-110144.325 ± 33211.578
Change at Day 28 (n=26, 38)-183452.324 ± 22560.241-130613.019 ± 19255.852
Change at Day 56 (n=25, 33)-118129.436 ± 25397.042-156544.533 ± 22550.054
SecondaryChange From Baseline in Blood Biomarker Interleukin (IL)-6 (Initial Approach)

Blood was collected and serum biomarker IL-6 was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · pg/mL
Change From Baseline in Blood Biomarker Interleukin (IL)-6 (Initial Approach)
pg/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 41)-12.469 ± 0.782-11.904 ± 0.742
Change at Day 14 (n=33, 41)-1.973 ± 1.918-5.728 ± 1.730
Change at Day 28 (n=28, 40)-8.108 ± 2.360-7.243 ± 1.997
Change at Day 56 (n=27, 40)-11.665 ± 1.129-9.431 ± 0.937
SecondaryChange From Baseline in Blood Biomarker Interleukin (IL)-6 (Extended Approach)

Blood was collected and serum biomarker IL-6 was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · pg/mL
Change From Baseline in Blood Biomarker Interleukin (IL)-6 (Extended Approach)
pg/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=47, 45)-12.314 ± 0.652-11.802 ± 0.665
Change at Day 14 (n=43, 45)1.607 ± 2.543-6.069 ± 2.490
Change at Day 28 (n=33, 44)-7.587 ± 2.088-7.619 ± 1.838
Change at Day 56 (n=32, 44)-10.811 ± 1.064-9.604 ± 0.918
SecondaryChange From Baseline in Blood Biomarker Interleukin-1 Beta (IL-1β) (Initial Approach)

Blood was collected and serum biomarker IL-1β was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · pg/mL
Change From Baseline in Blood Biomarker Interleukin-1 Beta (IL-1β) (Initial Approach)
pg/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 41)1.274 ± 0.6820.378 ± 0.647
Change at Day 14 (n=33, 41)0.217 ± 0.3590.495 ± 0.324
Change at Day 28 (n=28, 40)0.657 ± 0.4310.541 ± 0.366
Change at Day 56 (n=27, 40)-0.003 ± 0.3290.464 ± 0.288
SecondaryChange From Baseline in Blood Biomarker IL-1β (Extended Approach)

Blood was collected and serum biomarker IL-1β was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · pg/mL
Change From Baseline in Blood Biomarker IL-1β (Extended Approach)
pg/mLRoflumilast 500 μgPlacebo
Change at Day 7 (n=47, 45)0.350 ± 0.590-1.002 ± 0.602
Change at Day 14 (n=43, 45)-0.394 ± 0.355-0.841 ± 0.349
Change at Day 28 (n=33, 44)-0.139 ± 0.414-0.757 ± 0.368
Change at Day 56 (n=32, 44)-0.799 ± 0.333-0.806 ± 0.312
SecondaryChange From Baseline in Blood Biomarker C-reactive Protein (CRP) (Initial Approach)

Blood was collected and serum biomarker CRP was measured using Roche Modular Analytics E 170 Module. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · mg/liter(L)
Change From Baseline in Blood Biomarker C-reactive Protein (CRP) (Initial Approach)
mg/liter(L)Roflumilast 500 μgPlacebo
Change at Day 7 (n=37, 41)-15.579 ± 0.485-16.518 ± 0.461
Change at Day 14 (n=33, 41)4.836 ± 4.249-4.369 ± 3.812
Change at Day 28 (n=28, 38)-9.179 ± 4.110-8.018 ± 3.533
Change at Day 56 (n=26, 40)-14.889 ± 1.395-13.057 ± 1.133
SecondaryChange From Baseline in Blood Biomarker C-reactive Protein (CRP) (Extended Approach)

Blood was collected and serum biomarker CRP was measured using Roche Modular Analytics E 170 Module. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · mg/L
Change From Baseline in Blood Biomarker C-reactive Protein (CRP) (Extended Approach)
mg/LRoflumilast 500 μgPlacebo
Change at Day 7 (n=47, 45)-16.166 ± 0.410-16.901 ± 0.417
Change at Day 14 (n=43, 45)5.720 ± 3.600-5.257 ± 3.518
Change at Day 28 (n=33, 42)-8.250 ± 3.802-9.254 ± 3.375
Change at Day 56 (n=31, 44)-15.152 ± 1.219-13.793 ± 1.034
SecondaryChange From Baseline in Blood Biomarker Fibrinogen (Initial Approach)

Biomarker Plasma fibrinogen was determined using the method described by Clauss. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · umol/L
Change From Baseline in Blood Biomarker Fibrinogen (Initial Approach)
umol/LRoflumilast 500 μgPlacebo
Change at Day 7 (n=34, 39)-3.916 ± 0.286-3.976 ± 0.261
Change at Day 14 (n=33, 38)0.404 ± 0.625-0.184 ± 0.571
Change at Day 28 (n=27, 36)0.210 ± 0.6760.014 ± 0.567
Change at Day 56 (n=26, 38)-2.127 ± 0.625-1.144 ± 0.515
SecondaryChange From Baseline in Blood Biomarker Fibrinogen (Extended Approach)

Biomarker Plasma fibrinogen was determined using the method described by Clauss. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · umol/L
Change From Baseline in Blood Biomarker Fibrinogen (Extended Approach)
umol/LRoflumilast 500 μgPlacebo
Change at Day 7 (n=44, 43)-3.971 ± 0.246-3.839 ± 0.244
Change at Day 14 (n=43, 42)0.051 ± 0.521-0.148 ± 0.519
Change at Day 28 (n=32, 40)0.147 ± 0.599-0.091 ± 0.524
Change at Day 56 (n=31, 42)-2.155 ± 0.533-1.162 ± 0.462
SecondaryChange From Baseline in Blood Biomarker Glucose (Initial Approach)

Blood was collected and analyzed for serum glucose levels. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · mmol/L
Change From Baseline in Blood Biomarker Glucose (Initial Approach)
mmol/LRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 41)1.617 ± 0.4261.027 ± 0.397
Change at Day 14 (n=33, 41)1.000 ± 0.3000.432 ± 0.270
Change at Day 28 (n=28, 40)0.067 ± 0.156-0.020 ± 0.129
Change at Day 56 (n=27, 40)0.255 ± 0.2720.226 ± 0.230
SecondaryChange From Baseline in Blood Biomarker Glucose (Extended Approach)

Blood was collected and analyzed for serum glucose levels. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · mmol/L
Change From Baseline in Blood Biomarker Glucose (Extended Approach)
mmol/LRoflumilast 500 μgPlacebo
Change at Day 7 (n=46, 45)1.767 ± 0.4080.973 ± 0.408
Change at Day 14 (n=42, 45)0.942 ± 0.2540.364 ± 0.246
Change at Day 28 (n=33, 44)0.061 ± 0.139-0.008 ± 0.119
Change at Day 56 (n=32, 43)0.189 ± 0.2350.215 ± 0.210
SecondaryChange From Baseline in Forced Expiratory Volume (FEV1) (Initial Approach)

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · liters
Change From Baseline in Forced Expiratory Volume (FEV1) (Initial Approach)
litersRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 41)0.051 ± 0.0310.010 ± 0.029
Change at Day 14 (n=33, 41)0.083 ± 0.0350.028 ± 0.031
Change at Day 28 (n=28, 40)0.095 ± 0.0370.001 ± 0.031
Change at Day 56 (n=27, 40)0.064 ± 0.0390.010 ± 0.033
SecondaryChange From Baseline in Forced Expiratory Volume (FEV1) (Extended Approach)

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · liters
Change From Baseline in Forced Expiratory Volume (FEV1) (Extended Approach)
litersRoflumilast 500 μgPlacebo
Change at Day 7 (n=47, 45)0.063 ± 0.0270.012 ± 0.028
Change at Day 14 (n= 43, 45)0.062 ± 0.0290.018 ± 0.029
Change at Day 28 (n=33, 44)0.084 ± 0.031-0.003 ± 0.028
Change at Day 56 (n=32, 44)0.050 ± 0.0340.005 ± 0.030
SecondaryChange From Baseline in Forced Vital Capacity (FVC) (Initial Approach)

Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · liters
Change From Baseline in Forced Vital Capacity (FVC) (Initial Approach)
litersRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 41)0.002 ± 0.0600.057 ± 0.056
Change at Day 14 (n=33, 41)0.039 ± 0.0620.166 ± 0.056
Change at Day 28 (n=28, 40)0.039 ± 0.0720.075 ± 0.062
Change at Day 56 (n=27, 40)0.044 ± 0.0720.086 ± 0.062
SecondaryChange From Baseline in Forced Vital Capacity (FVC) (Extended Approach)

Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · liters
Change From Baseline in Forced Vital Capacity (FVC) (Extended Approach)
litersRoflumilast 500 μgPlacebo
Change at Day 7 (n=47, 45)0.048 ± 0.0520.062 ± 0.053
Change at Day 14 (n=43, 45)0.046 ± 0.0540.146 ± 0.053
Change at Day 28 (n=33, 44)0.053 ± 0.0620.067 ± 0.057
Change at Day 56 (n=32, 44)0.034 ± 0.0650.084 ± 0.058
SecondaryChange From Baseline in FEV1/FVC (Initial Approach)

FEV1/FVC is the percentage of the vital capacity which is expired in the first second of maximal expiration. In healthy patients the FEV1/FVC is usually around 70%. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · percent
Change From Baseline in FEV1/FVC (Initial Approach)
percentRoflumilast 500 μgPlacebo
Change at Day 7 (n=37, 41)1.575 ± 0.933-1.064 ± 0.870
Change at Day 14 (n=33, 41)1.874 ± 1.012-1.796 ± 0.914
Change at Day 28 (n=28, 40)2.350 ± 1.138-1.029 ± 0.982
Change at Day 56 (n=27, 40)1.636 ± 0.951-1.669 ± 0.828
SecondaryChange From Baseline in FEV1/FVC (Extended Approach)

FEV1/FVC is the percentage of the vital capacity which is expired in the first second of maximal expiration. In healthy patients the FEV1/FVC is usually around 70%. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.

Time frame:
Baseline and Day 7, Day 14, Day 28 and Day 56
Reported as:
Least squares mean · percent
Change From Baseline in FEV1/FVC (Extended Approach)
percentRoflumilast 500 μgPlacebo
Change at Day 7 (n=47, 45)1.282 ± 0.795-1.128 ± 0.799
Change at Day 14 (n=43, 45)1.394 ± 0.850-1.830 ± 0.834
Change at Day 28 (n=33, 44)2.045 ± 0.974-1.198 ± 0.888
Change at Day 56 (n=32, 44)1.393 ± 0.827-1.881 ± 0.765
SecondaryChronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Initial Approach)

The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Mean · score on a scale
Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Initial Approach)
score on a scaleRoflumilast 500 μgPlacebo
Week 1 (n=27, 34)19.4 ± 6.6519.2 ± 7.20
Week 2 (n=28, 36)17.1 ± 7.8617.1 ± 7.48
Week 3 (n=24, 37)15.9 ± 7.8416.0 ± 7.90
Week 4 (n=23, 38)15.1 ± 7.8515.8 ± 8.42
Week 5 (n=21, 37)14.2 ± 7.4114.9 ± 8.04
Week 6 (n=19, 37)12.9 ± 6.8515.4 ± 8.23
Week 7 (n=20, 33)13.9 ± 8.9314.7 ± 8.48
Week 8 (n=18, 30)12.8 ± 7.8515.6 ± 8.25
SecondaryChronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Extended Approach)

The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Mean · score on a scale
Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Extended Approach)
score on a scaleRoflumilast 500 μgPlacebo
Week 1 (n=37, 38)20.4 ± 7.2619.3 ± 7.03
Week 2 (n=37, 40)18.2 ± 8.5417.2 ± 7.32
Week 3 (n=29, 41)16.2 ± 8.0816.1 ± 7.73
Week 4 (n=27, 42)16.0 ± 8.2115.9 ± 8.26
Week 5 (n=25, 41)14.0 ± 7.2815.1 ± 7.93
Week 6 (n=23, 41)12.9 ± 6.5815.4 ± 8.12
Week 7 (n=24, 37)13.5 ± 8.3814.8 ± 8.44
Week 8 (n=19, 30)13.0 ± 7.6815.6 ± 8.25
SecondaryChange From Stable State in Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Initial Approach)

The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst). A negative change from Baseline indicates improvement. Covariates for MMRM are stable state value, treatment, time point, and treatment by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · score on a scale
Change From Stable State in Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Initial Approach)
score on a scaleRoflumilast 500 μgPlacebo
Change at Week 1 (n=27, 34)6.448 ± 1.5032.695 ± 1.096
Change at Week 2 (n=28, 36)3.778 ± 1.2390.804 ± 0.911
Change at Week 3 (n=24, 37)2.002 ± 0.9150.278 ± 0.669
Change at Week 4 (n=23, 38)0.559 ± 0.7390.277 ± 0.536
Change at Week 5 (n=21, 37)-0.412 ± 0.613-0.392 ± 0.448
Change at Week 6 (n=19, 37)-0.924 ± 0.411-0.062 ± 0.297
Change at Week 7 (n=20, 33)-0.228 ± 0.3420.048 ± 0.253
Change at Week 8 (n=18, 30)0.002 ± 0.059-0.048 ± 0.044
SecondaryChange From Stable State in Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Extended Approach)

The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst). A negative change from Baseline indicates improvement. Covariates for MMRM are stable state value, treatment, time point, and treatment by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · scores on a scale
Change From Stable State in Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Extended Approach)
scores on a scaleRoflumilast 500 μgPlacebo
Week 1 (n=37, 38)6.232 ± 1.4243.009 ± 1.052
Week 2 (n=37, 40)3.558 ± 1.1781.074 ± 0.876
Week 3 (n=29, 41)2.044 ± 0.8470.458 ± 0.627
Week 4 (n=27, 42)0.545 ± 0.7320.429 ± 0.534
Week 5 (n=25, 41)-0.347 ± 0.621-0.170 ± 0.459
Week 6 (n=23, 41)-0.668 ± 0.402-0.043 ± 0.295
Week 7 (n=24, 37)-0.121 ± 0.3100.014 ± 0.232
Week 8 (n=19, 30)-0.010 ± 0.061-0.031 ± 0.045
SecondaryExacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Initial Approach)

The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status.

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Mean · score on a scale
Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Initial Approach)
score on a scaleRoflumilast 500 μgPlacebo
Week 1 (n=25, 35)45.2 ± 8.5445.1 ± 8.50
Week 2 (n=28, 36)41.2 ± 11.3942.4 ± 9.07
Week 3 (n=24, 38)38.8 ± 11.2240.0 ± 10.22
Week 4 (n=23, 38)38.3 ± 11.0040.2 ± 11.26
Week 5 (n=21, 37)35.9 ± 11.1139.1 ± 10.55
Week 6 (n=19, 37)35.1 ± 9.7539.4 ± 11.05
Week 7 (n=20, 34)35.6 ± 13.6938.7 ± 12.05
Week 8 (n=18, 32)34.4 ± 11.5039.4 ± 11.34
SecondaryExacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Extended Approach)

The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status.

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Mean · score on a scale
Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Extended Approach)
score on a scaleRoflumilast 500 μgPlacebo
Week 1 (n=35, 39)45.6 ± 9.1945.0 ± 8.39
Week 2 (n=37, 40)42.0 ± 11.0742.3 ± 8.81
Week 3 (n=29, 42)39.0 ± 11.2739.9 ± 9.82
Week 4 (n=27, 42)38.8 ± 11.3740.3 ± 10.90
Week 5 (n=25, 41)35.3 ± 11.0339.1 ± 10.13
Week 6 (n=23, 41)33.9 ± 10.4539.4 ± 10.62
Week 7 (n=24, 38)34.3 ± 13.0938.7 ± 11.52
Week 8 (n=19, 33)34.0 ± 11.3039.6 ± 11.25
SecondaryChange From Stable State in Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Initial Approach)

The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, time point, treatment by time point and baseline by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · score on a scale
Change From Stable State in Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Initial Approach)
score on a scaleRoflumilast 500 μgPlacebo
Change at Week 1 (n=25, 35)6.182 ± 3.2714.753 ± 2.385
Change at Week 2 (n=28, 36)4.423 ± 2.5381.558 ± 1.864
Change at Week 3 (n=24, 38)2.080 ± 2.0410.317 ± 1.494
Change at Week 4 (n=23, 38)0.002 ± 2.0030.657 ± 1.459
Change at Week 5 (n=21, 37)-1.058 ± 1.748-0.307 ± 1.276
Change at Week 6 (n=19, 37)-1.688 ± 1.015-0.002 ± 0.738
Change at Week 7 (n=20, 34)-0.773 ± 0.6980.002 ± 0.514
Change at Week 8 (n=18, 32)-0.190 ± 0.259-0.154 ± 0.191
SecondaryChange From Stable State in Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Extended Approach)

The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, time point, treatment by time point and baseline by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · scores on a scale
Change From Stable State in Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Extended Approach)
scores on a scaleRoflumilast 500 μgPlacebo
Week 1 (n=35, 39)7.163 ± 2.8594.697 ± 2.077
Week 2 (n=37, 40)4.839 ± 2.2591.433 ± 1.652
Week 3 (n=29, 42)2.988 ± 1.8700.179 ± 1.363
Week 4 (n=27, 42)0.909 ± 1.8610.743 ± 1.344
Week 5 (n=25, 41)-0.657 ± 1.554-0.318 ± 1.129
Week 6 (n=23, 41)-0.889 ± 0.976-0.140 ± 0.706
Week 7 (n=24, 38)-0.311 ± 0.654-0.075 ± 0.479
Week 8 9n=19, 33)-0.240 ± 0.244-0.115 ± 0.178
SecondaryChange From Stable State in Diaries Peak Expiratory Flow (PEF) Weekly Average (Initial Approach)

Morning post-medication PEF (the best of 3 attempts measured with a mini-Wright peak-flow meter) was recorded in a daily diary. A positive change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · liters/minute
Change From Stable State in Diaries Peak Expiratory Flow (PEF) Weekly Average (Initial Approach)
liters/minuteRoflumilast 500 μgPlacebo
Change at Week 1 (n=37, 38)-16.551 ± 5.144-9.915 ± 4.442
Change at Week 2 (n=35, 40)-6.067 ± 4.564-0.304 ± 3.899
Change at Week 3 (n=35, 40)-4.996 ± 3.9140.687 ± 3.360
Change at Week 4 (n=29, 39)-4.595 ± 3.421-0.420 ± 2.737
Change at Week 5 (n=28, 38)-3.557 ± 4.061-1.224 ± 3.287
Change at Week 6 (n=27, 37)-3.795 ± 4.546-5.559 ± 3.680
Change at Week 7 (n=27, 36)-7.178 ± 5.212-4.186 ± 4.264
Change at Week 8 (n=27, 35)-2.877 ± 5.388-0.956 ± 4.418
SecondaryChange From Stable State in Diaries Peak Expiratory Flow (PEF) Weekly Average (Extended Approach)

Morning post-medication PEF (the best of 3 attempts measured with a mini-Wright peak-flow meter) was recorded in a daily diary. A positive change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · liters/minute
Change From Stable State in Diaries Peak Expiratory Flow (PEF) Weekly Average (Extended Approach)
liters/minuteRoflumilast 500 μgPlacebo
Change at Week 1 (n=46, 42)-13.958 ± 4.147-8.447 ± 3.865
Change at Week 2 (n=44, 44)-5.776 ± 3.7721.029 ± 3.488
Change at Week 3 (n=44, 44)-5.360 ± 3.6762.038 ± 3.421
Change at Week 4 (n=37, 43)-6.660 ± 3.5461.133 ± 3.126
Change at Week 5 (n=33, 42)-5.568 ± 3.8470.269 ± 3.396
Change at Week 6 (n=32, 41)-2.186 ± 3.515-4.596 ± 3.076
Change at Week 7 (n=31, 40)-8.513 ± 4.544-1.974 ± 3.952
Change at Week 8 (n=31, 39)-4.563 ± 4.7410.950 ± 4.091
SecondaryChange From Stable State in Diaries Symptom Score Weekly Average (Initial Approach)

Any increase in the following respiratory symptoms: dyspnea, sputum purulence, sputum amount, wheeze, sore throat, cough, fever, symptoms of a common cold, ie, nasal congestion and discharge over the previous 24 hours were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · score on a scale
Change From Stable State in Diaries Symptom Score Weekly Average (Initial Approach)
score on a scaleRoflumilast 500 μgPlacebo
Change at Week 1 (n=38, 42)2.930 ± 0.2862.587 ± 0.254
Change at Week 2 (n=37, 42)1.130 ± 0.3141.331 ± 0.272
Change at Week 3 (n=35, 42)0.906 ± 0.2990.790 ± 0.258
Change at Week 4 (n=30, 40)0.552 ± 0.2980.922 ± 0.248
Change at Week 5 (n=29, 39)0.413 ± 0.3050.882 ± 0.254
Change at Week 6 (n=28, 39)0.141 ± 0.3100.681 ± 0.258
Change at Week 7 (n=27, 37)0.442 ± 0.2940.673 ± 0.243
Change at Week 8 (n=27, 36)0.626 ± 0.3610.612 ± 0.297
SecondaryChange From Stable State in Diaries Symptom Score Weekly Average (Extended Approach)

Any increase in the following respiratory symptoms: dyspnea, sputum purulence, sputum amount, wheeze, sore throat, cough, fever, symptoms of a common cold, ie, nasal congestion and discharge over the previous 24 hours were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · score on a scale
Change From Stable State in Diaries Symptom Score Weekly Average (Extended Approach)
score on a scaleRoflumilast 500 μgPlacebo
Change at Week 1 (n=48, 46)3.110 ± 0.2572.593 ± 0.246
Change at Week 2 (n=47, 46)1.171 ± 0.2851.402 ± 0.267
Change at Week 3 (n=44, 46)0.850 ± 0.2670.802 ± 0.250
Change at Week 4 (n=38, 44)0.751 ± 0.3120.924 ± 0.282
Change at Week 5 (n=34, 43)0.437 ± 0.2870.907 ± 0.259
Change at Week 6 (n=33, 43)0.041 ± 0.2570.661 ± 0.231
Change at Week 7 (n=31, 41)0.503 ± 0.2470.533 ± 0.216
Change at Week 8 (n=31, 40)0.451 ± 0.2740.530 ± 0.237
SecondaryChange From Stable State in Diaries Treatment Score Weekly Average (Initial Approach)

Any changes in the participant's usual treatment were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · score on a scale
Change From Stable State in Diaries Treatment Score Weekly Average (Initial Approach)
score on a scaleRoflumilast 500 μgPlacebo
Change at Week 1 (n=38, 42)0.849 ± 0.1940.769 ± 0.174
Change at Week 2 (n=37, 42)0.682 ± 0.1900.804 ± 0.167
Change at Week 3 (n=35, 42)0.281 ± 0.1150.188 ± 0.099
Change at Week 4 (n=30, 40)0.185 ± 0.1180.217 ± 0.099
Change at Week 5 (n=29, 39)0.130 ± 0.1230.263 ± 0.103
Change at Week 6 (n=28, 39)0.128 ± 0.1300.204 ± 0.108
Change at Week 7 (n=27, 37)0.112 ± 0.1170.135 ± 0.097
Change at Week 8 (n=27, 36)0.122 ± 0.1010.127 ± 0.084
SecondaryChange From Stable State in Diaries Treatment Score Weekly Average (Extended Approach)

Any changes in the participant's usual treatment were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · score on a scale
Change From Stable State in Diaries Treatment Score Weekly Average (Extended Approach)
score on a scaleRoflumilast 500 μgPlacebo
Change at Week 1 (n=48, 46)0.787 ± 0.1700.730 ± 0.162
Change at Week 2 (n=47, 46)0.767 ± 0.1720.780 ± 0.161
Change at Week 3 (n=44, 46)0.338 ± 0.1030.177 ± 0.095
Change at Week 4 (n=38, 44)0.379 ± 0.1440.206 ± 0.129
Change at Week 5 (n=34, 43)0.191 ± 0.1070.244 ± 0.096
Change at Week 6 (n=33, 43)0.127 ± 0.1070.196 ± 0.096
Change at Week 7 (n=31, 41)0.179 ± 0.1160.156 ± 0.103
Change at Week 8 (n=31, 40)0.084 ± 0.0860.171 ± 0.075
SecondaryChange From Stable State in Diaries Hours Out of the Home Weekly Average (Initial Approach)

Estimates of the length of time the participants were out of their own home on the previous day were recorded in a daily diary. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · hours
Change From Stable State in Diaries Hours Out of the Home Weekly Average (Initial Approach)
hoursRoflumilast 500 μgPlacebo
Change at Week 1 (n=34, 34)-1.313 ± 0.416-0.105 ± 0.391
Change at Week 2 (n=34, 38)-0.974 ± 0.359-0.328 ± 0.333
Change at Week 3 (n=34, 40)-1.077 ± 0.3740.226 ± 0.335
Change at Week 4 (n=28, 39)-1.131 ± 0.414-0.306 ± 0.354
Change at Week 5 (n=26, 38)-0.826 ± 0.4650.280 ± 0.407
Change at Week 6 (n=25, 35)-1.154 ± 0.448-0.062 ± 0.386
Change at Week 7 (n=26, 35)-1.194 ± 0.449-0.340 ± 0.394
Change at Week 8 (n=26, 34)-0.812 ± 0.5320.037 ± 0.458
SecondaryChange From Stable State in Diaries Hours Out of the Home Weekly Average (Extended Approach)

Estimates of the length of time the participants were out of their own home on the previous day were recorded in a daily diary. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Reported as:
Least squares mean · hours
Change From Stable State in Diaries Hours Out of the Home Weekly Average (Extended Approach)
hoursRoflumilast 500 μgPlacebo
Change at Week 1 (n=42, 38)-1.472 ± 0.353-0.276 ± 0.344
Change at Week 2 (n=43, 42)-1.305 ± 0.319-0.472 ± 0.307
Change at Week 3 (n=42, 44)-1.314 ± 0.3430.099 ± 0.324
Change at Week 4 (n=35, 43)-1.328 ± 0.357-0.266 ± 0.325
Change at Week 5 (n=31, 42)-0.833 ± 0.4020.158 ± 0.369
Change at Week 6 (n=30, 39)-1.271 ± 0.372-0.247 ± 0.344
Change at Week 7 (n=30, 39)-1.144 ± 0.363-0.478 ± 0.333
Change at Week 8 (n=30, 38)-0.714 ± 0.443-0.068 ± 0.401
SecondaryExacerbation Length (Initial Approach)

Exacerbation length is the period from start of increased symptoms to end of increased symptoms; the last day of an exacerbation was to be followed by 2 days without symptom entries in the diary.

Time frame:
8 Weeks
Reported as:
Median · days
Exacerbation Length (Initial Approach)
daysRoflumilast 500 μgPlacebo
Exacerbation Length (Initial Approach)12.0 (8.0 to 18.0)14.0 (10.0 to 17.0)
SecondaryExacerbation Length (Extended Approach)

Exacerbation length is the period from start of increased symptoms to end of increased symptoms; the last day of an exacerbation was to be followed by 2 days without symptom entries in the diary.

Time frame:
8 Weeks
Reported as:
Median · days
Exacerbation Length (Extended Approach)
daysRoflumilast 500 μgPlacebo
Exacerbation Length (Extended Approach)13.0 (9.0 to 19.0)14.0 (11.0 to 17.0)
SecondaryChange From Baseline in Aortic Pulse Wave Velocity in a Subset of Participants (Initial Approach)

Carotid-femoral aortic pulse wave velocity (aPWV) will be measured in a subset of participants to determine changes in arterial stiffness. A negative change from Baseline indicates improvement. Covariates for MMRM are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Days 14 and 28
Reported as:
Least squares mean · meters/second
Change From Baseline in Aortic Pulse Wave Velocity in a Subset of Participants (Initial Approach)
meters/secondRoflumilast 500 μgPlacebo
Change at Day 14 (n=18, 24)-0.047 ± 0.337-0.343 ± 0.290
Change at Day 28 (n=14, 24)-0.380 ± 0.413-0.474 ± 0.321
SecondaryChange From Baseline in Aortic Pulse Wave Velocity in a Subset of Participants (Extended Approach)

Carotid-femoral aortic pulse wave velocity (aPWV) will be measured in a subset of participants to determine changes in arterial stiffness. A negative change from Baseline indicates improvement. Covariates for MMRM are baseline value, treatment, visit, and treatment by visit interaction.

Time frame:
Baseline and Days 14 and 28
Reported as:
Least squares mean · meters/second
Change From Baseline in Aortic Pulse Wave Velocity in a Subset of Participants (Extended Approach)
meters/secondRoflumilast 500 μgPlacebo
Change at Day 14 (n=28, 28)-0.128 ± 0.247-0.326 ± 0.245
Change at Day 28 (n=19, 28)-0.316 ± 0.323-0.511 ± 0.273

Adverse events

Collected over Signing of informed consent until Follow-up Visit (Up to 56 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast 500 μg (Initial Approach)—4/38 (10.5%)35/38 (92.1%)
Placebo (Initial Approach)—1/43 (2.3%)25/43 (58.1%)
Roflumilast 500 µg (Extended Approach)—4/48 (8.3%)44/48 (91.7%)
Placebo (Extended Approach)—1/47 (2.1%)28/47 (59.6%)
Most frequent serious events
Most frequent serious events
EventRoflumilast 500 μg (Initial Approach)Placebo (Initial Approach)Roflumilast 500 µg (Extended Approach)Placebo (Extended Approach)
ConstipationGastrointestinal disorders1/380/431/480/47
PneumoniaInfections and infestations1/380/431/480/47
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/380/431/480/47
Supraventricular tachycardiaCardiac disorders1/380/431/480/47
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/381/430/481/47
Most frequent other events
Showing 10 of 14
Most frequent other events
EventRoflumilast 500 μg (Initial Approach)Placebo (Initial Approach)Roflumilast 500 µg (Extended Approach)Placebo (Extended Approach)
DiarrhoeaGastrointestinal disorders25/3810/4332/4811/47
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders17/3813/4319/4815/47
InsomniaPsychiatric disorders12/382/4314/482/47
NauseaGastrointestinal disorders6/383/439/483/47
DizzinessNervous system disorders6/381/436/481/47
Decreased appetiteMetabolism and nutrition disorders4/382/436/482/47
HeadacheNervous system disorders3/382/434/482/47
Gastrooesophageal reflux diseaseGastrointestinal disorders2/381/433/481/47
VomitingGastrointestinal disorders0/380/433/481/47
Abdominal painGastrointestinal disorders2/381/430/480/47

Baseline characteristics

Full Analysis set consisted of all randomized patients who received at least 1 dose of investigational medicinal product (IMP)

Age, Customized
Age, Customized(participants)Roflumilast 500 μgPlaceboTotal
≤ 65 years71118
> 65 years313263
Gender
Gender(Participants)Roflumilast 500 μgPlaceboTotal
Female161531
Male222850
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Roflumilast 500 μgPlaceboTotal
Asian213
White364278
Smoking status
Smoking status(participants)Roflumilast 500 μgPlaceboTotal
Non-smoker000
Current smoker81119
Former smoker303262
Baseline COPD Assessment Test (CAT) Total Score
Baseline COPD Assessment Test (CAT) Total Score(participants)Roflumilast 500 μgPlaceboTotal
< 10235
≥ 10162541
Missing201535
Weight Category by Body Mass Index (BMI)
Weight Category by Body Mass Index (BMI)(participants)Roflumilast 500 μgPlaceboTotal
Underweight303
Normal Weight151833
Overweight111526
Obese9918
Missing011
Chronic Bronchitis
Chronic Bronchitis(participants)Roflumilast 500 μgPlaceboTotal
No141731
Yes242650
Historical Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
Historical Chronic Obstructive Pulmonary Disease (COPD) Exacerbations(participants)Roflumilast 500 μgPlaceboTotal
< 2282856
≥ 2101525
08

Study locations

2 sites
  • Academic Unit of Respiratory Medicine, Royal Free Hospital, Jadwiga A. Wedzicha
    London, NW3 2PF, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Mackay AJ, Patel ARC, Singh R, Sapsford RJ, Donaldson GC, Prasad N, Goehring UM, Nip TK, Wedzicha JA. Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 Sep 1;196(5):656-659. doi: 10.1164/rccm.201612-2518LE. No abstract available. PubMed 28146642 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 2 years 7 months after primary completion. A results delay was requested in Feb 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2011
First posted
Nov 17, 2011
Start
Feb 2012
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results delay requested
Feb 20, 2015
Results first posted
Oct 24, 2016
Last update
Feb 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01473758
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 17, 2011
Start date
Feb 2012
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Oct 24, 2016
Last update
Feb 14, 2017

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion